KYZATREX
Testosterone replacement therapy (TRT) in adult men with low/no testosterone due to certain medical conditions
ApprovedActive
Key Facts
Indication
Testosterone replacement therapy (TRT) in adult men with low/no testosterone due to certain medical conditions
Phase
Approved
Status
Active
Company
About Marius Pharmaceuticals
Marius Pharmaceuticals is a clinical-stage biotech company developing novel oral hormone therapies, with its flagship product, KYZATREX, approved and commercially available in the US and Canada for testosterone replacement therapy (TRT) in adult men with certain medical conditions. The company is actively researching broader applications of testosterone therapy in comorbidities like obesity and type 2 diabetes, as well as exploring its potential in women's health. Led by CEO Shalin Shah, Marius combines a commercial product with an ambitious R&D pipeline, positioning itself at the intersection of metabolic health and endocrinology.
View full company profile